ArticleFrontiers in molecular biosciences2020
ZFP36 Binds With PRC1 to Inhibit Tumor Growth and Increase 5-Fu Chemosensitivity of Hepatocellular Carcinoma.
Article in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Repositioning Antihistamine for Cancer Therapy: Clemizole as a Template for the Design of Liver Tissue-Targeting Epigenetic-Modifying Agents.Journal of medicinal chemistry · 2026Article
- ZFP36 promotes ferroptosis and mitochondrial dysfunction and inhibits malignant progression in osteosarcoma by regulating the E2F1/ATF4 axis.Journal of pharmaceutical analysis · 2025Article
- Protein regulator of cytokinesis 1 regulates autophagy in hepatitis B virus‑associated liver cancer development.Oncology reports · 2025Article
- Transcriptome Analysis of Choroidal Endothelium Links Androgen Receptor Role to Central Serous Chorioretinopathy.European journal of ophthalmology · 2024Article
- MiR-934 Exacerbates Malignancy of Gastric Cancer Cells by Targeting ZFP36.Iranian journal of public health · 2023Article
- An in-silico approach leads to explore six genes as a molecular signatures of lung adenocarcinoma.American journal of cancer research · 2023Article
- ZFP36 Inhibits Tumor Progression of Human Prostate Cancer by Targeting CDK6 and Oxidative Stress.Oxidative medicine and cellular longevity · 2022Article
- Screening of ferroptosis-related genes in sepsis-induced liver failure and analysis of immune correlation.PeerJ · 2022Article
- RNA-binding proteins modulate drug sensitivity of cancer cells.Emerging topics in life sciences · 2021Article
- ZFP36L2 Role in Thyroid Functionality.International journal of molecular sciences · 2021Article
- Identification and validation of a novel ferroptosis-related gene model for predicting the prognosis of gastric cancer patients.PloS one · 2021Article
- Single-Cell Transcriptome Analysis of Chronic Antibody-Mediated Rejection After Renal Transplantation.Frontiers in immunology · 2021Article
Corrections and comments
- Retraction · 2025-01-22Concerns/Issues about Data · Concerns/Issues about Image · Duplication of Data · Duplication of/in Image · Euphemisms for Duplication · Investigation by Journal/Publisher · Investigation by Third Party · Objections by Author(s) · · See also: https://pubpeer.com/publications/16AFC0120C08B7137EE462C236C0E3
- Retracted
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the fifth common cause of tumor-related death worldwide. ZFP36, a RNA-binding protein, decreases in many cancers and its role in HCC remains unclear. This study aimed to investigate the underlying mechanisms by which ZFP36 inhibited HCC progression and increased fluorouracil (5-Fu) sensitivity. We found that ZFP36 was downregulated and PRC1 was upregulated in HCC tissues compared with adjacent non-tumor tissues.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.